Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2018

Publisher Name :
Date: 17-Jul-2018
No. of pages: 40

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2018

Summary

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors.

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 1 and 6 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.

The latest report Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2018, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)

- The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects

- The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Overview
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Companies Involved in Therapeutics Development
Agilvax Inc
Bavarian Nordic A/S
MedImmune LLC
Visterra Inc
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drug Profiles
AX-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit RSV-G and F Proteins for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MVA-RSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
respiratory syncytial virus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-3D3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-RSV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Dormant Products
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Product Development Milestones
Featured News & Press Releases
Mar 06, 2018: Bavarian Nordic Announces Additional Positive Data from a Phase 2 Study of its Universal RSV Vaccine
Nov 09, 2017: Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
Sep 21, 2017: Bavarian Nordic Provides Update on its Universal RSV Vaccine
Jun 27, 2017: Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
Feb 23, 2017: Updated Phase 1 Data Show Bavarian Nordic's Vaccine Candidate Induces a Broad and Durable Immune Response against RSV
Dec 14, 2016: Bavarian Nordic Announces Completion of Enrollment for Phase 2 Clinical Trial of RSV Vaccine
Oct 18, 2016: Bavarian Nordic Announces Initiation of Phase 2 Clinical Trial of RSV Vaccine
Sep 29, 2016: Bavarian Nordic Announces Presentation Of Phase 1 Data For Its RSV Vaccine At International RSV Symposium
Jul 06, 2016: Agilvax Receives SBIR Grant To Advance Development Of A VLP Based RSV Vaccine
May 23, 2016: Bavarian Nordic Announces Positive Top Line Results from a Phase 1 Trial of a Novel, Broad Spectrum RSV Vaccine in Healthy Adult and Elderly Populations
Aug 18, 2015: Bavarian Nordic Initiates Phase 1 Clinical Trial of MVA-BN in Respiratory Syncitial Virus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Agilvax Inc, H2 2018
Pipeline by Bavarian Nordic A/S, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Visterra Inc, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Endocrinology Drugs Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 119
    In 2017, the global Endocrinology Drugs market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Endocrinology Drugs market based on company, product type, application and key regions. This report studies the global market size of Endocrinology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focu......
  • Global Liver Cirrhosis Therapeutics Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 114
    In 2017, the global Liver Cirrhosis Therapeutics market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Liver Cirrhosis Therapeutics market based on company, product type, application and key regions. This report studies the global market size of Liver Cirrhosis Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and......
  • Global B4GN4 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 115
    In 2017, the global B4GN4 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the B4GN4 Antibody market based on company, product type, application and key regions. This report studies the global market size of B4GN4 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global B3GL2 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 118
    In 2017, the global B3GL2 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the B3GL2 Antibody market based on company, product type, application and key regions. This report studies the global market size of B3GL2 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global C1GLT Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 110
    In 2017, the global C1GLT Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the C1GLT Antibody market based on company, product type, application and key regions. This report studies the global market size of C1GLT Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global CGAT2 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 113
    In 2017, the global CGAT2 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the CGAT2 Antibody market based on company, product type, application and key regions. This report studies the global market size of CGAT2 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the cons......
  • Global GALNT1 Antibody Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 127
    In 2017, the global GALNT1 Antibody market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the GALNT1 Antibody market based on company, product type, application and key regions. This report studies the global market size of GALNT1 Antibody in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the c......
  • Global Fucosyltransferase 3 (enzyme) FUT3 Protein Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 112
    In 2017, the global Fucosyltransferase 3 (enzyme) FUT3 Protein market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the Fucosyltransferase 3 (enzyme) FUT3 Protein market based on company, product type, application and key regions. This report studies the global market size of Fucosyltransferase 3 (enzyme) FUT3 Protein in key regions like North America, Europe,......
  • Global cDNA Clone Vector Market Insights, Forecast to 2025
    Published: 14-Dec-2018        Price: US 3900 Onwards        Pages: 116
    In 2017, the global cDNA Clone Vector market size was million US$ and is forecast to million US in 2025, growing at a CAGR of from 2018. The objectives of this study are to define, segment, and project the size of the cDNA Clone Vector market based on company, product type, application and key regions. This report studies the global market size of cDNA Clone Vector in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs